<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03799900</url>
  </required_header>
  <id_info>
    <org_study_id>RAP-PK-12</org_study_id>
    <nct_id>NCT03799900</nct_id>
  </id_info>
  <brief_title>Assessment of Abuse Potential of Rapastinel in Humans</brief_title>
  <official_title>A Two-part, Single-dose, Randomized, Double-blind, Placebo and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Rapastinel in Healthy, Non-dependent, Adult Recreational Polydrug Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Naurex, Inc, an affiliate of Allergan plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Naurex, Inc, an affiliate of Allergan plc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on the pharmacological class of rapastinel, this study will be conducted to evaluate
      the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR
      antagonist that is a Schedule III dissociative anesthetic, and placebo in recreational
      polydrug users.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">March 29, 2019</completion_date>
  <primary_completion_date type="Actual">March 24, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum effect (Emax) for &quot;At this Moment&quot; Drug Liking visual analog scale (VAS).</measure>
    <time_frame>Treatment Phase: Pre-dose and up to 24 hours post-dose</time_frame>
    <description>The drug liking VAS measures the participant's liking for the drug and is scored from 0 to 100, with 0 reflecting &quot;Strong disliking&quot; and 100 reflecting &quot;Strong liking&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum effect (Emax)</measure>
    <time_frame>Treatment Phase: Pre-dose and up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum effect (Emin)</measure>
    <time_frame>Treatment Phase: Pre-dose and up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Emax (TEmax)</measure>
    <time_frame>Treatment Phase: Pre-dose and up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Emin (TEmin)</measure>
    <time_frame>Treatment Phase: Pre-dose and up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time averaged area under the effect curve (TA_AUE)</measure>
    <time_frame>Treatment Phase: Hour 0 and up to 24 Hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma drug concentration (Cmax)</measure>
    <time_frame>Treatment Phase: Pre-dose and up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve from time 0 to the last quantifiable concentration (AUClast)</measure>
    <time_frame>Treatment Phase: Pre-dose and up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Part 1: 6 weeks, Part 2: 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of abnormal electrocardiograms</measure>
    <time_frame>Part 1: 6 weeks, Part 2: 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia-Suicide Severity Rating Scale</measure>
    <time_frame>Part 1: 6 weeks, Part 2: 9 weeks</time_frame>
    <description>The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (least severe) to 5 (most severe).</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Human Abuse Potential</condition>
  <arm_group>
    <arm_group_label>Part 1, Cohort 1: Ketamine Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Some participants will be administered a single IV dose of ketamine on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Some participants will be administered a single IV dose of placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 2: Ketamine Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Some participants will be administered a single IV dose of ketamine on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Some participants will be administered a single IV dose of placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 3 (Optional): Ketamine High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optional: some participants will be administered a single IV dose of ketamine on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 3 (Optional): Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Optional: some participants will be administered a single IV dose of placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Qualification Phase: Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IV ketamine on Day 1 and placebo on Day 2 in a randomized crossover manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Qualification Phase: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive IV ketamine on Day 2 and placebo on Day 1 in a randomized crossover manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Treatment Phase: Rapastinel Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Treatment Phase: Rapastinel Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Treatment Phase: Rapastinel High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Treatment Phase: Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Treatment Phase: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapastinel</intervention_name>
    <description>During the Treatment Phase in Part 2, participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.</description>
    <arm_group_label>Part 2, Treatment Phase: Rapastinel High Dose</arm_group_label>
    <arm_group_label>Part 2, Treatment Phase: Rapastinel Low Dose</arm_group_label>
    <arm_group_label>Part 2, Treatment Phase: Rapastinel Medium Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Part 1
Part 2, Qualification Phase:
Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner
Part 2, Treatment Phase:
Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.</description>
    <arm_group_label>Part 1, Cohort 1: Ketamine Low Dose</arm_group_label>
    <arm_group_label>Part 1, Cohort 2: Ketamine Medium Dose</arm_group_label>
    <arm_group_label>Part 1, Cohort 3 (Optional): Ketamine High Dose</arm_group_label>
    <arm_group_label>Part 2, Qualification Phase: Ketamine</arm_group_label>
    <arm_group_label>Part 2, Treatment Phase: Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Part 1
Part 2, Qualification Phase:
Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner
Part 2, Treatment Phase:
Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.</description>
    <arm_group_label>Part 1, Cohort 1: Placebo</arm_group_label>
    <arm_group_label>Part 1, Cohort 2: Placebo</arm_group_label>
    <arm_group_label>Part 1, Cohort 3 (Optional): Placebo</arm_group_label>
    <arm_group_label>Part 2, Qualification Phase: Placebo</arm_group_label>
    <arm_group_label>Part 2, Treatment Phase: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must be a current recreational polydrug user

          -  Have a supine systolic blood pressure (BP) ≥ 95 mm Hg and ≤ 145 mg Hg, or supine
             diastolic BP ≥ 50 mm Hg and ≤ 90 mm Hg at the Screening Visit.

          -  Have negative test results for benzoylecgonine (cocaine), methadone, barbiturates,
             amphetamines, benzodiazepines, alcohol, oxycodone and other opioids, and phencyclidine
             at any admission

          -  Able, as assessed by the investigator, and willing to follow study instructions and
             likely to complete all required study visits

        Exclusion Criteria:

          -  Evidence of drug or alcohol dependence (excluding nicotine and caffeine) within the
             past 2 years

          -  Suicidal risk based on the opinion of the principal investigator (or appropriately
             trained designee)

          -  History of violent or psychotic behavior when taking psychedelic drugs, or unwilling
             to take a drug that might alter perception in a controlled setting

          -  Have taken or require concomitant treatment with any CNS depressants, or cannot safely
             discontinue these medications within 14 days (or 5 half-lives, whichever is longer)
             before study treatment administration

          -  Previously participated in an investigational study of rapastinel.

          -  Participation in any other clinical investigation using an experimental drug within 30
             days, 5 half-lives or twice the duration of the biological effect of the study
             treatment (whichever is longer), prior to study treatment administration or is
             concurrently enrolled in any clinical trial, judged not to be scientifically or
             medically compatible with this study

          -  Consumption of alcohol within 72 hours before administration of study treatment

          -  Breastfeeding

          -  Unable to refrain from consuming caffeine or xanthine-containing compounds such as
             tea, coffee, soft drinks, energy sports drinks or chocolate (more than 48 oz/day) from
             48 hours before administration of study treatment.

          -  Have consumed dietary supplements or other foods or beverages that may affect various
             drug metabolizing enzymes and transporters (eg, grapefruit, grapefruit juice,
             grapefruit-containing beverages), vegetables from the mustard green family (eg, kale,
             broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard), and
             charbroiled meats within 14 days prior to dosing or unable to refrain from consumption
             during the study.

          -  The ability to tolerate IV ketamine as judged by the Investigator, based on available
             safety data, as well as pharmacodynamic data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheng Fang Su</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research Inc</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>November 15, 2018</study_first_submitted>
  <study_first_submitted_qc>January 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2019</study_first_posted>
  <last_update_submitted>May 14, 2019</last_update_submitted>
  <last_update_submitted_qc>May 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

